Clinical trial NCT05012319: Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19
Official title: A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Covid19
Lead sponsor: Salmaniya Medical Complex
Sponsor class: OTHER_GOV
First posted: 2021-08-19
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a randomized, double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in healthy adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection.
Primary purpose: TREATMENT

Brief summary: Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection. thru facility).

Detailed description: Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection.

Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria:
* 18 years and above.
* COVID-19 infection Confirmed with a laboratory SARS-CoV-2 RT-PCR nasal swab or antigen test. COVID-19 test specimen must be collected 48 hours prior to Screenings.
* Mild COVID-19 Infection defined as:

  * No Pneumonia (negative by chest auscultation or Chest X Ray).
  * No Shortness of breath.
  * No Tachypnea (respiratory rate \<20 breathes/min)
  * No Hypoxia (Oxygen saturation \>93% on RA)
  * Fever \<38 degrees.
  * No Chest Pain.
  * No Mental Status Change.
* Asymptomatic participants must be high risk defined as (any of the following):

  * Smokers (at least 5 cigarettes per day)
  * BMI (\> 40 kg/m2)
  * History of cardiac or chronic lung disease
  * Clotting predisposing conditions (hemophilia, von Willebrand's disease)
  * Sickle cell disease
  * Immunocompromised such as HIV , cancer , on immunosuppressant medications

Exclusion Criteria:

* Participants diagnosed with another (non-COVID-19) respiratory infection.
* Participants with a current tracheostomy or laryngectomy.
* Participants who are receiving concomitant respiratory therapy such as oxygen, positive airway pressure or ventilatory support. NOTE: Positive airway pressure for obstructive sleep apnea is permitted if the treatment was established with good compliance for at least 3 months before study enrollment.
* Participants with newly diagnosed illnesses that are not deemed stable by the participant's primary care physician), based on Investigator assessment of medical history during Screening.
* Participants who use intranasally dosed drugs, prescriptions or over-the-counter medications such as fluticasone.
* Participants who need hospitalization for reasons other than COVID-19 infection.
* Participants who are unable to safely self-administer the nasal spray as directed.
* Clinical signs indicative of moderate, severe, or critical COVID severity symptoms (requirement for supplemental oxygen, limitation of activities due to COVID-19 symptoms).
* Females who are breastfeeding, pregnant, or attempting to become pregnant.
* Participants who have experienced symptoms of COVID-19 for more than 7 days prior to randomization.
* Participants who have any other condition that, in the opinion of the Investigator, would interfere with a participant's ability to adhere to the protocol (eg, participants who are mentally or neurologically disabled and who are considered not fit for their participation in the study), interfere with assessment of the investigational product, or compromise the safety of the participant, or the quality of the data.

Primary outcomes:
measure: efficacy of NONS compared to placebo in participants with COVID-19 to reduce the need of urgent care
timeFrame: 6 months
Secondary outcomes:
measure: efficacy of NONS compared to placebo in participants with COVID-19 to reduce mortality
timeFrame: 6 months
measure: efficacy of NONS compared to placebo in participants with COVID-19 on viral load reduction
timeFrame: 6 months
measure: efficacy of NONS compared to placebo in participants with COVID-19 to reduce time of clinical symptoms improvement
timeFrame: 6 months
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: 6 months
Other outcomes:
Locations:
city: A'ali
country: Bahrain
facility: Abdulla Kanoo Center,
state: Building 556
Study officials:
References: